Deciphera Pharmaceuticals Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Axsome To Pay $312,500 To Settle Patent Infringement Litigation With Baudax Axsome Therapeutics, Inc.

Deciphera Pharmaceuticals (NASDAQ:DCPH) is scheduled to announce Q4 earnings results on Tuesday, February 8th, after market close.The consensus EPS Estimate is -$1.40 and the

Let us take a look at three biotech/drug companies that are slated to release quarterly results on Feb 8.

Biotech stocks managed to close the week ending Feb. 4 with gains. Stocks recovered along with the broader markets early in the week, but came under pressure midweek amid negative reaction to some bi

Deciphera Pharmaceuticals, Inc. (DCPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Deciphera Pharmaceuticals, Inc. (DCPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the frenetic pace of the week that

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present virtually at the 40th Annual J.P

Blueprint Medicines' (BPMC) Ayvakit, approved to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors, has seen strong uptake since approval. Other pipeline candidates are also progressing well

This article was originally published on TipRanks.com Deciphera Pharmaceuticals (NASDAQ: DCPH) has received marketing authorization for QINLOCK (ripretinib) in the U. The post MHRA Authorizes Decipheras QINLOCK in the U.K. appeared first on Smarter Analyst .

Shares of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) have received an average recommendation of Hold from the thirteen analysts that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating on the company. The average []

During the last session, Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH)s traded shares were 11.84 million, with the beta value of the company hitting 1.48. At the end of the trading day, the stocks price was $9.91, reflecting an intraday gain of 8.54% or $0.78. The 52-week high for the DCPH share is $61.92, that puts it down Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH) Rose 23.01% From Its 52-Week Low, But YTD Numbers Fell -82.64%. Heres What You Need To Know At This Time Read More »

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) was the recipient of a significant increase in short interest in November. As of November 30th, there was short interest totalling 2,830,000 shares, an increase of 36.1% from the November 15th total of 2,080,000 shares. Currently, 7.6% of the companys stock are short sold. Based on an average trading volume of []

Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) price on Thursday, December 09, fall -0.69% below its previous days close as a downside momentum from buyers pushed the stocks value to $8.58. A look at the stocks price movement, the close in the last trading session was $8.64, moving within a range at $8.53 and $8.94. The beta value Unlocking Growth Opportunity In Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH) Read More »